U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3O2S
Molecular Weight 243.326
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2-IMINOBIOTIN

SMILES

[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=N)N2

InChI

InChIKey=WWVANQJRLPIHNS-ZKWXMUAHSA-N
InChI=1S/C10H17N3O2S/c11-10-12-6-5-16-7(9(6)13-10)3-1-2-4-8(14)15/h6-7,9H,1-5H2,(H,14,15)(H3,11,12,13)/t6-,7-,9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H17N3O2S
Molecular Weight 243.326
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

2-Iminobiotin (2-IB) is a cyclic guanidino analog of biotin (Vitamin B7) and combined neuronal and inducible (but not endothelial) nitric oxide synthase inhibitor that has been demonstrated to improve neuroprotection in animal models of hypoxic-ischemic Brain Injury. While the exact mechanism of action has yet to be defined, 2-Iminobiotin potentially protects against hypoxic-ischemic brain damage by preventing nitric oxide or peroxynitrite-induced mitochondrial damage. In preclinical models, 2-Iminobiotin provides gender-specific neuroprotection against hypoxia-ischemia in neonatal rats by a NO-independent mechanism.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
21.8 nM [Ki]
37.5 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
22541 ng/mL
6 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
34175 ng/mL
12 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
1808 ng/mL
0.6 mg/kg single, intravenous
2-IMINOBIOTIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
16448 ng × h/mL
6 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
39956 ng × h/mL
12 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
1528 ng × h/mL
0.6 mg/kg single, intravenous
2-IMINOBIOTIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.12 h
6 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
2.37 h
12 mg/kg 6 times / day multiple, intravenous
2-IMINOBIOTIN plasma
Homo sapiens
1.48 h
0.6 mg/kg single, intravenous
2-IMINOBIOTIN plasma
Homo sapiens

Doses

AEs

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
Route of Administration: Intravenous
In Vitro Use Guide
Neuronal IMR-32 cells were exposed to hypoxia employing an enzymatic hypoxia system and were thereafter incubated with various concentrations of 2-IB (10 to 300ng/ml). Cell damage, metabolic activity and generation of reactive oxygen species were quantified using colorimetric/fluorometric lactate dehydrogenase (LDH), tetrazolium-based (MTS) and reactive oxygen species assays. Proteome profiling arrays were performed to evaluate the regulation of cell stress protein expression by hypoxia and 2-IB. Seven hours of hypoxia led to morphological changes in IMR-32 cultures, increased neuronal cell damage, reduction of metabolic activity and enhanced reactive oxygen species production. Post-hypoxic application of 2-IB (30ng/ml) attenuated hypoxia-induced LDH release and increased metabolic activity of IMR-32 cells, while reactive oxygen species production was only by trend decreased.
Substance Class Chemical
Record UNII
HXH71NRQ5C
Record Status Validated (UNII)
Record Version